Health Care · Laboratory Analytical Instruments · Nasdaq · CIK 1831915 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $4.38Day −1.79%Mkt cap $566M1Y +21.7%Off 52W high −29.1%Vol (1Y) 56.5%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,253 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest3.9% of sh out |
| Days to cover5.5d |
| 13F net flow (QoQ)+1.81% |
| Top-10 13F concentration70.0% |
| Next report (est.)2026-08-06 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$204.2M |
| Earnings (TTM)-$74.0M |
| ROE−18.0% |
| Net margin−33.0% |
| ROIC−11.6% |
| Sales growth 3Y308.2% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−13.3% |
| 1Y+21.7% |
| 3Y−51.1% |
| 5Y−79.9% |
| Since incept. (ann.)−24.5% |
Total return through 2026-07-29 · series begins 2021-07-26. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)56.5% |
| Ann. volatility (3Y)64.8% |
| Sharpe (1Y)0.56 |
| Sharpe (3Y)−0.05 |
| Max drawdown (1Y)−42.9% |
| Max drawdown (3Y)−74.6% |
| Beta (3Y vs SPY)2.19 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| BlackRock, Inc. | 17.0M | $74M | 13.23% | −1.0% |
| Topline Capital Management, LLC | 7.1M | $31M | 5.50% | −5.1% |
| HHLR ADVISORS, LTD. | 6.7M | $29M | 5.18% | +0.0% |
| MILLENNIUM MANAGEMENT LLC | 6.3M | $27M | 4.89% | +32.4% |
| Boston Partners | 5.8M | $25M | 4.51% | +15.9% |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.8M | $21M | 3.71% | new |
| STATE STREET CORP | 4.1M | $18M | 3.21% | −0.6% |
| GEODE CAPITAL MANAGEMENT, LLC | 2.8M | $12M | 2.20% | +1.6% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-07 | — | — | $44.1M | +6.5% |
| 2025-12-31 | 2026-02-26 | — | — | $62.1M | +8.1% |
| 2025-09-30 | 2025-11-05 | — | — | $52.3M | +1.5% |
| 2025-06-30 | 2025-08-06 | — | — | $45.6M | −2.2% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-06 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Reportable 100%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
